NO931561D0 - Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar - Google Patents

Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar

Info

Publication number
NO931561D0
NO931561D0 NO931561A NO931561A NO931561D0 NO 931561 D0 NO931561 D0 NO 931561D0 NO 931561 A NO931561 A NO 931561A NO 931561 A NO931561 A NO 931561A NO 931561 D0 NO931561 D0 NO 931561D0
Authority
NO
Norway
Prior art keywords
scars
inflammation
inhibitors
treatment
application
Prior art date
Application number
NO931561A
Other languages
English (en)
Other versions
NO931561L (no
Inventor
Eckhard Schueler
Juergen Roemisch
Eric-Paul Paques
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO931561D0 publication Critical patent/NO931561D0/no
Publication of NO931561L publication Critical patent/NO931561L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO93931561A 1992-04-30 1993-04-29 Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar NO931561L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (de) 1992-04-30 1992-04-30 Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen

Publications (2)

Publication Number Publication Date
NO931561D0 true NO931561D0 (no) 1993-04-29
NO931561L NO931561L (no) 1993-11-01

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931561A NO931561L (no) 1992-04-30 1993-04-29 Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar

Country Status (16)

Country Link
EP (1) EP0567816A1 (no)
JP (1) JPH069425A (no)
KR (1) KR930021179A (no)
CN (1) CN1080873A (no)
AU (1) AU3822993A (no)
CA (1) CA2095207A1 (no)
CZ (1) CZ76893A3 (no)
DE (1) DE4214215A1 (no)
HU (1) HUT65755A (no)
IL (1) IL105521A0 (no)
MX (1) MX9302519A (no)
NO (1) NO931561L (no)
PL (1) PL298748A1 (no)
SK (1) SK41593A3 (no)
UY (1) UY23572A1 (no)
ZA (1) ZA933023B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
DK1159974T3 (da) 1993-07-19 2007-11-26 Angiotech Pharm Inc Antiangiogene sammensætninger indeholdende taxol og en ikke-bionedbrydelig bærer og deres anvendelse
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
KR20010042402A (ko) * 1998-04-01 2001-05-25 로잘란드 앤 칼도르 피부 상처의 치료를 위한 프로테아제 억제제의 용도
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
MXPA01011025A (es) 1999-04-29 2002-11-07 Ista Pharmaceuticals Inc Metodos bioquimicos que eliminan las cicatrices, opacificacion y la bruma de la cornea.
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (ja) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション クライアントサーバーシステム、オブジェクトのプール方法および記憶媒体
AU1123001A (en) 1999-10-27 2001-05-08 Alexandra Lucas Compositions and methods for preventing and treating transplant rejection
JP2001247458A (ja) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd トラネキサム酸亜鉛化合物を含む糖尿病治療剤
ATE453402T1 (de) 2000-09-29 2010-01-15 Viron Therapeutics Inc Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
JP2004511297A (ja) 2000-10-16 2004-04-15 コナー メドシステムズ, インコーポレイテッド 有益な薬剤を搬送するための拡張可能な医療装置
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
CN101977626A (zh) * 2008-01-21 2011-02-16 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
TWI763960B (zh) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 一種預防或治療骨關節炎的方法及藥物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
DE69031271T2 (de) * 1989-12-20 1998-02-26 Biotech Australia Pty Ltd Varianten von pai-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
HUT65755A (en) 1994-07-28
EP0567816A1 (de) 1993-11-03
CZ76893A3 (en) 1994-01-19
CN1080873A (zh) 1994-01-19
KR930021179A (ko) 1993-11-22
AU3822993A (en) 1993-11-04
PL298748A1 (en) 1993-12-27
SK41593A3 (en) 1993-11-10
IL105521A0 (en) 1993-08-18
DE4214215A1 (de) 1993-11-04
CA2095207A1 (en) 1993-10-31
MX9302519A (es) 1993-10-01
JPH069425A (ja) 1994-01-18
NO931561L (no) 1993-11-01
HU9301272D0 (en) 1993-07-28
ZA933023B (en) 1994-10-31
UY23572A1 (es) 1993-05-04

Similar Documents

Publication Publication Date Title
NO931561D0 (no) Anvendelse av inhibitorer av plasminogenaktivatorer for behandling av betennelse og saar
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
DK0661966T3 (da) Sammensætning og fremgangsmåde til ulcusforebyggelse og - behandling
PL333505A1 (en) Benzamido-aldehydes and their application as inhibitors of cysteinic proteases
NO943353D0 (no) Kombinasjoner av ACE-inhibitorer og diuretiske midler
NO930681D0 (no) Fremgangsmaate og anordning for ikke-kontakt plasma-polering og utjevning av ensartet tynnede substrater
DK0596122T3 (da) Fremgangsmåde til omvikling og omviklet genstand
IS4805A (is) Aðferð til meðhöndlunar og lyfjasamsetning
NO965563D0 (no) Behandling og profylakse av osteoporese
NO971900D0 (no) Blandinger og behandling av multippel sklerose
NO931779D0 (no) Fremgangsmaate for behandling av kondensater av ammoniakk og urea
NO985214D0 (no) Inhibitorer for produksjon av s-CD23 og sekresjon av TNF
NO960242D0 (no) Fremgangsmåte for deaktivering og ödeleggelser av mikroorganismer
NO172838C (no) Fremgangsmaate og anlegg for behandling av avfallsprodukter
NO932342D0 (no) Fremgangsmaate og innretning for fremstilling av pakker med amorfe staalstrimler for produksjon av transformatorskjermer
NO952568D0 (no) Behandling av cellulosemateriale og blandinger for anvendelse for dette
IL111501A0 (en) Pharmaceutical compositions comprising lys-plasminogen and tissue plasminogen activator (t-PA) for the treatment of coronary thrombosis
NO961113D0 (no) Behandling og forebyggelse av prostatakreft
NO951932L (no) Behandling av infertilitet og forökning av fertiliseringskapasiteter
NO970118L (no) Forbindelse og fremgangsmåte for behandling av hårtap
AU612562B2 (en) A composition comprising a plasmin inhibitor and a plasminogen activator for the treatment of thrombosis
EP0502470A3 (en) Compounds for the treatment of inflammation and allergy
NO950778D0 (no) Kloning og ekspresjon av
NO934599D0 (no) Fremgangsmaate og anordning for reduksjon av hudvev
AU3286893A (en) Therapeutic device and method of treatment